In vivo effects of partial phosphorothioated AT1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensive rats.
暂无分享,去创建一个
U. Galderisi | L. Berrino | F. Rossi | G. Di Bernardo | E. Piegari | M. Cipollaro | A. Cascino | F. Esposito | F. Rossi
[1] A. Giordano,et al. Antisense inhibitory effect: A comparison between 3′‐partial and full phosphorothioate antisense oligonucleotides , 1999, Journal of cellular biochemistry.
[2] J. Summerton,et al. A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. , 1997, Antisense & nucleic acid drug development.
[3] D. Chadwick,et al. Oligonucleotides as therapeutic agents , 1997 .
[4] U. Galderisi,et al. Myotonic dystrophy: antisense oligonucleotide inhibition of DMPK gene expression in vitro. , 1996, Biochemical and biophysical research communications.
[5] C. Stein,et al. Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.
[6] D. Wielbo,et al. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin , 1993, Regulatory Peptides.
[7] S. Crooke. Therapeutic applications of oligonucleotides. , 1992, Bio/technology.
[8] P. Timmermans,et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). , 1990, The Journal of pharmacology and experimental therapeutics.
[9] R. Tallarida,et al. Manual of Pharmacologic Calculations: With Computer Programs , 1984 .